Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Terns schedules to bring a third candidate into the clinic this year, TERN-501, a thyroid hormone receptor (THR) beta-agonist.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

JANUARY 27, 2021

These include in-vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities.

In-Vitro 52

In-Vitro Containment Drugs Production 52

Pfizer

DECEMBER 20, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., Microsomal triglyceride transfer protein inhibitor: lomitapide.

Drugs 69

Drugs Licensing Licensing Containment 69

Velocity Clinical Research

JUNE 27, 2023

Novo Nordisk announced that a biologics license application for the insulin icodec has been submitted for FDA review. “It’s a chemical, a small molecule that also acts on the GLP-1 receptor, but because it’s not a protein it’s not degraded by enzymes,” said Dr. Frias.

Insulin 52

Insulin Trials Hormones Clinical Trials 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 10, 2021

We expect to further advance our late stage endocrinology pipeline with the anticipated approval and launch in the United States and the approval in Europe of TransCon hGH for pediatric growth hormone deficiency, and to obtain phase 3 results for TransCon PTH in adult hypoparathyroidism. ?. . .

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

Pfizer

NOVEMBER 23, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., Microsomal triglyceride transfer protein inhibitor: lomitapide.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

MAY 15, 2021

SLIM OVER 55 is THE ONLY program for women over 55 that is especially designed for your body who has gone through menopause and needs to get all the hormones back in balance! Each of the Slim Over 55 meals are perfectly balanced with precise nutrients, carbohydrates, proteins, vitamins and the healthiest of fats.

Production 52

Production Sales Hormones Vaccination 52

The Pharma Data

APRIL 23, 2021

Dostarlimab was discovered by AnaptysBio and licensed to TESARO, Inc., under a Collaboration and Exclusive License Agreement signed in March 2014. related adverse reactions, which may be severe or fatal, can occur in patients treated with antibodies blocking the programmed cell death protein?1 Immune-Mediated Adverse Reactions.

Antibody 40

Antibody Hormones Containment Licensing 40

The Pharma Data

DECEMBER 27, 2020

Proteasomes play an important role in cell function and growth by breaking down proteins that are damaged or no longer needed. i KYPROLIS has been shown to block proteasomes, leading to an excessive build-up of proteins within cells. We also market or plan to market in China additional oncology products licensed from Amgen Inc.,

Production 52

Production Drugs Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 3, 2021

Initial data from LUMAKRAS in combination with a mitogen-activated protein kinase kinase (MEK) inhibitor and LUMAKRAS in combination with an oral EGFR inhibitor are planned to be submitted for presentation at a Q4 2021 medical conference. An acapatamab dose escalation study has initiated for patients with NSCLC expressing PSMA. Tezepelumab.

Sales 52

Sales Production Antibody Development 52

The Pharma Data

MAY 4, 2021

Panzyga (immune globulin intravenous [human] ifas 10% liquid preparation) — In February 2021, Pfizer announced that the FDA approved the supplemental Biologics License Application (sBLA) for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

MAY 16, 2021

Will rejuvenate your body from the inside out while revving-up your fat burning hormones and rewinding years from your face, chin and neck faster than you imagined possible. . And recharge your #1 fat loss hormone, get lean and ripped fast, and turn back the clock on aging in less than 20-minutes a week.

Hormones 52

Hormones Sales Production Vaccination 52

XTalks

NOVEMBER 26, 2024

on these sales under an exclusive licensing agreement that allows Janssen to develop, produce and market daratumumab. Why it sold so well: Imbruvica is a kinase inhibitor that targets Bruton’s tyrosine kinase (BTK), a crucial protein in the B-cell receptor signaling pathway. Genmab earns royalties from Janssen Biotech, Inc.

Sales 105

Sales FDA Approval Drugs Marketing 105